Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Gains First Approval For Oral Factor Xa Inhibitor In Japan

This article was originally published in The Pink Sheet Daily

Executive Summary

Boehringer Ingelheim's Pradaxa has set the bar by showing superiority to standard-of-care warfarin, and Daiichi Sankyo has staked a lot on an ongoing Phase III comparison study of Lixiana (edoxaban) to warfarin for the prevention of thromboembolism in atrial fibrillation, expected to report in 2012.
Advertisement

Related Content

Pradaxa Review Shows FDA Doubts About The Power Of REMS To Change Prescribing Practices
Approval Highs And Lows For Leading Japanese Pharma; Dogged By Competitors And Nagging Supply Issues
Approval Highs And Lows For Leading Japanese Pharma; Dogged By Competitors And Nagging Supply Issues
Is It Better To Be First Or Best? Daiichi Sankyo Shifts R&D Priorities

Topics

Advertisement
UsernamePublicRestriction

Register

PS072151

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel